Patents Assigned to Wyeth LLC
  • ANTI-5T4 ANTIBODIES AND USES THEREOF
    Publication number: 20160185859
    Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 30, 2016
    Applicant: WYETH LLC
    Inventors: Erwin R. BOGHAERT, Nitin K. DAMLE, Philip Ross HAMANN, Kiran KHANDKE, Arthur KUNZ, Kimberly A. MARQUETTE, Lioudmila TCHISTIAKOVA, Davinder GILL, Sreekumar R. KODANGATTIL
  • PROCESSES FOR MAKING HYDRAZIDES
    Publication number: 20160176809
    Abstract: A method is disclosed for preparing hydrazides from hydrazine and an acyl chloride which comprises the steps of (a) preparing a stirred substantially uniform slurry comprising hydrazine and an inert solvent at low temperature; and (b) adding an acyl chloride continuously to said slurry. The method avoids or limits production of undesired bis-hydrazide by-products. The method is used to prepare 3-methyl-3-mercaptobutanoic acid hydrazide, a molecule used to link calicheamicin to a monoclonal antibody.
    Type: Application
    Filed: December 18, 2015
    Publication date: June 23, 2016
    Applicant: WYETH LLC
    Inventors: George Anello CHIARELLO, Ayman SAHLI
  • PROCESS FOR PREPARING PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATES
    Publication number: 20160158345
    Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.
    Type: Application
    Filed: February 12, 2016
    Publication date: June 9, 2016
    Applicant: Wyeth LLC
    Inventors: William P. Hausdorff, George Rainer Siber, Peter R. Paradiso
  • TIGECYCLINE COMPOSITIONS AND METHODS OF PREPARATION
    Publication number: 20160144036
    Abstract: The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.
    Type: Application
    Filed: January 29, 2016
    Publication date: May 26, 2016
    Applicant: Wyeth LLC
    Inventors: Mahdi B. FAWZI, Tianmin ZHU, Syed M. SHAH
  • Tumor-initiating cells and methods for using same
    Patent number: 9340774
    Abstract: Isolated and enriched tumor-initiating cell populations, methods for preparing the same, and uses thereof.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: May 17, 2016
    Assignee: Wyeth LLC
    Inventors: Marc Isaac Damelin, Kenneth G. Geles, Jonathon P. Golas, Erwin Boghaert, Bin-Bing S. Zhou
  • Oral formulations and lipophilic salts of methylnaltrexone
    Patent number: 9314461
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: April 19, 2016
    Assignee: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • IMPLANTABLE SHUNT OR CATHETER ENABLING GRADUAL DELIVERY OF THERAPEUTIC AGENTS
    Publication number: 20160089521
    Abstract: An implantable catheter or shunt for draining fluid from a body cavity. The catheter or shunt body has a wall structure that carries one or more therapeutic agents in a manner enabling release of the therapeutic agent from the wall structure in situ after surgical implantation of the catheter or shunt body. The therapeutic agent can be gradually released over time to prevent infection, inhibit tissue ingrowths, and/or provide some other desired medicinal purpose. As an example, the therapeutic agent can be rapamycin or an mTOR inhibitor. According to some contemplated embodiments of the present invention, the therapeutic agent carried by the catheter/shunt is rechargeable or refillable in situ so that the therapeutic agent can be gradually released from the catheter/shunt over the expected useful life of the catheter/shunt.
    Type: Application
    Filed: December 10, 2015
    Publication date: March 31, 2016
    Applicant: Wyeth LLC
    Inventors: Deborah L. Dragoon, Jonathan Marc Cohen
  • High-cell density fed-batch fermentation process for producing recombinant protein
    Patent number: 9279000
    Abstract: Methods for producing proteins, for example, recombinant meningococcal 2086 proteins, using fed-batch fermentation with continuous input of an inducer after achieving a threshold parameter, and optionally continuous input of a carbon source, for example, a constant rate input, to improve protein yields, as well as high density protein compositions and compositions for use in the methods of the present invention, are provided.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: March 8, 2016
    Assignee: Wyeth LLC
    Inventors: Wei-Qiang Willie Sun, Earl Joseph Pursell
  • Use of tau to monitor immunotherapy
    Patent number: 9272030
    Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: March 1, 2016
    Assignees: JANSSEN SCIENCES IRELAND UC, WYETH LLC
    Inventors: Ronald Black, Jack Steven Jacobsen, Lioudmila Tchistiakova, Angela Widom, Davinder Gill, Lars Ekman, Ivan Lieberburg, Michael Grundman, James Callaway, Keith M. Gregg, Wagner Zago, Manuel J. Buttini, Gene G. Kinney
  • Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
    Patent number: 9265784
    Abstract: A combination of a 4-anilino-3-cyanoquinoline compound (e.g. HKI-272, SKI-606, EKB-569) and a capecitabine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: February 23, 2016
    Assignee: WYETH LLC
    Inventors: Charles Michael Zacharchuk, Susan Elizabeth Quinn, Kenneth Kuan-Yuen Wang, Florence Marie Helene Binlich
  • Tigecycline compositions and methods of preparation
    Patent number: 9254328
    Abstract: The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: February 9, 2016
    Assignee: Wyeth LLC
    Inventors: Mahdi B. Fawzi, Tianmin Zhu, Syed M. Shah
  • Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive
    Patent number: 9238073
    Abstract: A pharmaceutical composition is provided which contains a water soluble acid salt of a sympathomimetic amine, e.g., pseudoephedrine, and an additive, e.g., a volatile amine or other odorant, that is co-distillable, e.g., by steam distillation, with the sympathomimetic amine and/or its derivatives, e.g., its free base.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: January 19, 2016
    Assignee: Wyeth LLC
    Inventors: David Hugh Giamalva, Gary Bruce Anderson
  • ANTI-NOTCH1 ANTIBODIES
    Publication number: 20160002331
    Abstract: The present invention provides for antibodies that bind to Notch1. The present disclosure also provides methods of making the antibodies, pharmaceutical compositions comprising these antibodies and methods of treating disorders with the antibodies and pharmaceutical compositions.
    Type: Application
    Filed: July 24, 2015
    Publication date: January 7, 2016
    Applicant: WYETH LLC
    Inventors: Kenneth G. GELES, Bin-Bing Stephen ZHOU, Lioudmila Gennadievna TCHISTIAKOVA, Yijie GAO, Joel BARD
  • Processes for making hydrazides
    Patent number: 9227924
    Abstract: A method is disclosed for preparing hydrazides from hydrazine and an acyl chloride which comprises the steps of (a) preparing a stirred substantially uniform slurry comprising hydrazine and an inert solvent at low temperature; and (b) adding an acyl chloride continuously to said slurry. The method avoids or limits production of undesired bis-hydrazide by-products. The method is used to prepare 3-methyl-3-mercaptobutanoic acid hydrazide, a molecule used to link calicheamicin to a monoclonal antibody.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: January 5, 2016
    Assignee: WYETH LLC
    Inventors: George Anello Chiarello, Ayman Sahli
  • Treatment regimen utilizing neratinib for breast cancer
    Patent number: 9211291
    Abstract: An extended regimen for treatment of HER-2/neu overexpressed/amplified cancer is described, with involves delivering a course of neratinib therapy to HER-2/neu overexpressed/amplified cancer patients following the completion of surgical and adjuvant therapy. The neratinib regimen may be continued for upwards of twelve months to five years. Also provided are pharmaceutical kits designed to facilitate compliance with the regimen.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: December 15, 2015
    Assignee: WYETH LLC
    Inventors: Anna Berkenblit, Florence Marie Helene Binlich, Paul Goss
  • Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
    Patent number: 9211264
    Abstract: The present invention provides an oral pharmaceutical formulation comprising coated spheroids of a kinase inhibitor such as neratinib, which formulation is designed to reduce or eliminate side effects associated with existing oral formulations of kinase inhibitors.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: December 15, 2015
    Assignee: WYETH LLC
    Inventors: Sripriya Venkata Ramana Rao, Syed Muzafar Shah, Christopher Richard Diorio, Maja Vencl-Joncic, Eugene Murphy
  • Compositions relating to a mutant toxin and methods thereof
    Patent number: 9187536
    Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: November 17, 2015
    Assignee: Wyeth LLC
    Inventors: Annaliesa Sybil Anderson, Maninder K. Sidhu, Robert G. K. Donald, Kathrin Ute Jansen, Narender K. Kalyan, Justin Keith Moran, Mark E. Ruppen, Michael James Flint
  • Peripheral opioid receptor antagonists and uses thereof
    Patent number: 9180125
    Abstract: The present invention provides a compound of formula I: wherein X?, R1, and R2 are as defined herein, and compositions thereof.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: November 10, 2015
    Assignee: Wyeth, LLC
    Inventors: Nataliya Bazhina, George Joseph Donato, III, Steven R. Fabian, John Lokhnauth, Sreenivasulu Megati, Charles Melucci, Christian Ofslager, Niketa Patel, Galen Radebaugh, Syed M. Shah, Jan Szeliga, Huyi Zhang, Tianmin Zhu
  • PROCESSES FOR THE CONVERGENT SYNTHESIS OF CALICHEAMICIN DERIVATIVES
    Publication number: 20150315138
    Abstract: This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates.
    Type: Application
    Filed: May 13, 2015
    Publication date: November 5, 2015
    Applicant: WYETH LLC
    Inventors: Justin Keith MORAN, Jianxin GU
  • Treatment of sleep disturbances
    Patent number: 9155718
    Abstract: The present invention provides a new composition for treating pain-associated sleep disturbances, especially shortened sleep duration, comprising ibuprofen and diphenhydramine. The composition is further prepared as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule composition, to prevent interaction between the active ingredients.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: October 13, 2015
    Assignee: Wyeth LLC
    Inventors: Graham D. Cook, Todd S. Koch, David H. Giamalva, Justin Bianco, James J. Fort, Geraldine Doyle, Steven Cooper